Influenza, Human  >>  PREVNAR 13 (pneumococcal 13-valent conjugate vaccine)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

10 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
NCT00492557 / 2007-002326-29: Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults

Completed
3
1185
Europe
13-valent pneumococcal conjugate vaccine, 13vPnC + TIV
Pfizer
Pneumococcal Infections
02/08
02/08
NCT01000974 / 2013-004194-27: Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants

Completed
3
4003
US
GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108), Hiberix®, ActHIB™, Pentacel™, Pediarix™, Prevnar 13™, Rotarix™, Engerix™-B, Infanrix™
GlaxoSmithKline
Haemophilus Influenzae Type b
11/11
07/13
V419-006, NCT01340937 / 2011-004108-39: A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™

Completed
3
2808
NA
V419, PENTACEL™, Prevnar 13™, RotaTeq™, Recombivax HB vaccine
Merck Sharp & Dohme LLC, MCM Vaccines B.V.
Bacterial Infections, Virus Diseases
12/12
07/13
V419-007, NCT01341639 / 2010-021490-37: Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months

Completed
3
1250
NA
V419, INFANRIX™ hexa, RotaTeq, Prevenar 13, ProQuad™
MCM Vaccines B.V., Merck Sharp & Dohme LLC
Bacterial Infections, Virus Diseases
03/13
03/13
V419-005, NCT01337167 / 2011-004095-10: Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™

Completed
3
1473
NA
V419, DAPTACEL™, PedvaxHIB™, Prevnar 13™, RotaTeq™, V260, PENTACEL™, Recombivax HB vaccine, ActHIB™
Merck Sharp & Dohme LLC, MCM Vaccines B.V.
Bacterial Infections, Virus Diseases
05/13
05/13
NCT01553279 / 2011-002413-11: Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)

Completed
3
284
NA
V419, PR51, VAXELIS®, PREVNAR 13®, MCC-TT, NEISVAC-C®, MCC-CRM, MENJUGATE®, Hib-MCC, MENITORIX®, MMR Vaccine, M-M-RVAXPRO®
MCM Vaccines B.V.
Neisseria Meningitidis, Bacterial Infections, Virus Diseases
09/13
09/13
V419-008, NCT01480258 / 2010-021491-28: Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months

Completed
3
1315
NA
PR5I, V419, Vaxelis®, Rotavirus vaccine, Prevenar 13™, INFANRIX™ hexa
MCM Vaccines B.V., Merck Sharp & Dohme LLC
Bacterial Infections, Virus Diseases
10/13
10/13
NCT00521586: Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine

Completed
3
1116
US
13 valent pneumococcal conjugate vaccine, 0.5 mL dose of TIV and 13vPnC at dose 1, 0.5 mL dose of of placebo at dose 2, and 0.5ml dose of 13vPnC at year 5 will be administered into left deltoid muscle, 0.5 mL dose of TIV and of placebo at dose 1 and 0.5 mL dose of 13vPnC at dose 2 and year 5 will be administered into left deltoid muscle
Pfizer
Influenza
12/13
12/13
NCT01439360 / 2011-000758-41: An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children

Completed
3
12046
Europe, RoW
Quadrivalent seasonal influenza vaccine(Flu D-QIV) GSK2321138A, Havrix Junior, Prevenar 13, Varivax/ProVarivax, Varilrix
GlaxoSmithKline
Influenza
10/14
12/14
NCT01978093 / 2013-003459-39: Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age

Completed
3
600
US
Hib-MenCY-TT (MenHibrix®), Pediarix®, Rotarix®, Prevnar 13®, PedvaxHIB®, Havrix®
GlaxoSmithKline
Neisseria Meningitidis, Haemophilus Influenzae Type b
03/16
03/16

Download Options